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ABSTRACT
Objectives: For economic evaluations of chronic heart failure (CHF) man-
agement strategies, utilities are not currently available for disease proxies
commonly used in Markov models. Our objective was to estimate utilities
for New York Heart Association (NYHA) classiﬁcation and number of
cardiovascular rehospitalizations.
Methods: EuroQol 5D data from the Eplerenone Post-acute Myocardial
Infarction Heart Failure Efﬁcacy and Survival Study trial were used to
estimate utilities as a function of NYHA classiﬁcation and number of
cardiovascular rehospitalizations.
Results: In multivariate regression analyses adjusted for age (60 years),
female sex and absence of further comorbidities, utilities for NYHA
classes I–IV were 0.90, 0.83, 0.74, and 0.60 (P-value < 0.001 for trend).
For cardiovascular rehospitalizations 0, 1, 2 and 3, the associated utili-
ties were 0.88, 0.85, 0.84, and 0.82 (P-value < 0.001 for trend).
Conclusions: NYHA class and number of cardiovascular rehospitaliza-
tions are established proxies for CHF progression and can be linked to
utilities when used as health states in a Markov model. NYHA class
should be used when feasible.
Keywords: EQ-5D, heart failure, quality of life, quality-adjusted life-years,
utilities.
Background
Because of the increasing incidence and costs associated with
chronic heart failure (CHF) as well as health-care resource con-
straints, it is important to rationally evaluate new strategies in
the management of CHF with respect to their effectiveness and
cost-effectiveness [1]. In a recent systematic review, we identiﬁed
19 decision–analytic models evaluating new diagnostic and
therapeutic strategies in CHF [2]. Although most models used
thorough approaches, only six analyses reported clinical effec-
tiveness outcomes in terms of quality-adjusted life-years. More-
over, utilities that can be linked to common proxy health states
used in CHF decision–analytic cost–utility studies (e.g., using
Markov models) to represent disease progression are not avail-
able in the literature.
To address the limitations of currently available data, we used
primary data from the Eplerenone Post-acute Myocardial Infarc-
tion Heart Failure Efﬁcacy and Survival Study (EPHESUS) to
estimate utility values for patients with CHF according to New
York Heart Association (NYHA) classiﬁcation and number of
cardiovascular (CV) rehospitalizations for use in future CHF
decision models.
Methods
The EPHESUS trial was a multicenter randomized controlled trial
that investigated the effect of the aldosterone antagonist
eplerenone in 6232 patients with CHF after acute myocardial
infarction (AMI) [3]. End points of the study included all-cause
mortality, CV mortality and CV hospitalization.
In a subsample of 1628 patients, health-related quality of life
was assessed at months 0, 3, 6,12 and 18 using the EuroQol
(EQ-5D) [4,5]; all data were used in the analyses except the
baseline measurement that was excluded to mitigate the effect
of the AMI on the EQ-5D score. The EQ-5D is a generic
health status instrument that assesses ﬁve independent domains
(mobility, self-care, usual activities, pain/discomfort, anxiety/
depression). Recently, preference-based scoring algorithms have
been developed to allow conversion of EQ-5D health states into
population-speciﬁc utility weights. We used the utility value as a
dependent variable in our analyses, weighting the EQ-5D score
by the appropriate preference weight based on the subject’s
speciﬁc region of origin (United States—31%, Western Europe—
52%, Latin America—14%) [6–8].
We performed univariate and multivariate linear regression
analyses, employing a covariance modeling approach with an
unstructured covariance matrix to account for repeated measure-
ments and the high variability in utility estimates due to this
inherent subjectivity [9]. The independent variables included
NYHA classiﬁcation or number of CV hospitalizations (0, 1, 2,
3) between study intake and the follow-up time point. Analyses
were also adjusted for age, sex and cardiovascular comorbidities.
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Each model’s goodness of ﬁt was based on the Akaike informa-
tion criterion (AIC) [10].
Results
We based our analyses on 4575 measurements from 1395 sub-
jects with a mean age of 64  12 years. Patient’s characteristics
in the subgroup (sub) were not signiﬁcantly different from the full
EPHESUS (full) dataset except as related to male sex (full, 74%;
sub, 71%; P-value = 0.02), left ventricular ejection fraction (full,
33%  6; sub, 32%  7; P-value < 0.01), hypertension (full,
61%; sub, 55%; P-value < 0.01) and diabetes (full, 32%; sub,
26%; P-value < 0.01).
In univariate analyses, utilities associated with NYHA class
I–IV were 0.855 (95% conﬁdence interval [CI] 0.845–0.864),
0.771 (95% CI 0.761–0.781), 0.673 (95% CI 0.665–0.690) and
0.532 (95% CI 0.480–0.584), respectively (P-value for trend
<0.001). For number of rehospitalizations (0, 1, 2, 3), the
associated utilities in our univariate model were 0.812 (95% CI
0.802–0.821), 0.787 (95% CI 0.774–0.799), 0.769 (95% CI
0.751–0.787) and 0.746 (95% CI 0.727–0.765), respectively
(P-value for trend <0.001).
Plotting the means of the observed versus predicted utilities
stratiﬁed by deciles demonstrated an excellent ﬁt for the models
(R2 = 0.98 for both models). Adjustment for age, sex and cardio-
vascular co-morbidities did not affect the trend in either analysis.
Male sex was associated with signiﬁcantly higher utilities in both
analyses (0.04 for NYHA and 0.06 for rehospitalization).
Including age as a restricted cubic spline with knots at 50, 65
and 80 years improved the ﬁt of both models signiﬁcantly when
compared with simple linear functions. Other covariates that had
a signiﬁcant effect on utilities in both models included history of
an AMI before the entry of the study, history of a stroke or
transient ischemic attack, history of peripheral vascular disease
and history of chronic pulmonary obstructive disease. When the
interaction between age and disease proxy was included, it did
not affect the correlation between severity of disease and the
decrement in utility in the NYHA class model, but it did affect
the rehospitalization model with the lowest utility in the one
rehospitalization group. Assessment of models that described the
data best were based on AIC. Tables 1 and 2 provide the results
from the ﬁnal models that can be used to derive multivariate
adjusted estimates. For example, in multivariate analyses
adjusted for 60-year-old females without further co-morbidities,
utilities for NYHA classes I–IV were 0.90, 0.83, 0.74 and 0.60,
and 0.88, 0.85, 0.84 and 0.82 for cardiovascular rehospitaliza-
tions 0, 1, 2 and 3, respectively.
Discussion
Both proxies could be linked to utilities in a meaningful way and
thus be used in future decision–analytic models. The goal of this
analysis was not to develop a decision rule to predict an indi-
vidual patient’s utility as a function of these parameters over
time, but rather to provide a set of empirically derived utility
weights that can be easily linked to common disease proxies and
that may be used to represent health states in future Markov
models.
Both because of the subject matter of utility estimates and the
design of the EPHESUS trial, we faced a number of analytic
challenges. We ﬁrst chose to employ a covariance modeling
approach as opposed to treating each observation independently
because this allowed us to utilize all available information while
still accounting for the repeated measurements of each subject.
This choice was particularly important because individual utili-
ties are expected to have a high variability because they are
inﬂuenced by various unmeasured patient characteristics as well
as those covariates included in our model construct. In addition,
because our sample was derived from a population of recent AMI
patients, we chose to exclude the baseline utility assessment as
well as the impact of time from our modeling strategy.
Although we found a signiﬁcant interaction between our
proxies of interest and age, but given the complexity associated
with interpreting this interaction in the presence of age as a
restricted cubic spline, we ultimately decided to exclude it from
the model. Finally, despite its limitations, we felt that including
the results from the rehospitalization model was useful, because
number of rehospitalisations is a more objective end point than
NYHA class and is therefore favored as an end point in many
contemporary CHF trials. As a result, number of rehospitaliza-
tions is more likely to be available as a health state proxy for the
disease modeler than NYHA class.
Table 1 Results for the multivariate model based on NYHA class
Estimate Standard error P-value
Intercept 0.785 0.037 <0.001
NYHA class 1 Reference group
P-value for
trend <0.001
NYHA class 2 -0.071 0.006
NYHA class 3 -0.161 0.009
NYHA class 4 -0.302 0.026
Age (per year) 0.002 0.001 0.014
(Age - 50)3+ -2.22*E-06
(Age - 65)3+ 4.44*E-06
(Age - 80)3+ -2.22*E-06
Male 0.047 0.009 <0.001
History of diabetes -0.024 0.009 0.007
History of 2 AMIs -0.041 0.009 <0.001
History of stroke/TIA -0.057 0.013 <0.001
History of PVD -0.047 0.011 <0.001
History of COPD -0.027 0.012 0.023
US/Canadian origin Reference group
<0.001 (F-test)European origin -0.056 0.008
Latin American origin -0.005 0.012
AMI, acute myocardial infarction;COPD,chronic obstructive pulmonary disease;NYHA,New
York HeartAssociation; PVD,peripheral vessel disease;TIA, transitory ischemic attack;+, only
include term if difference > 0.
Table 2 Results for the multivariate model based on number of cardio-
vascular rehospitalizations
Estimate Standard error P-value
Intercept 0.759 0.040 <0.001
0 rehospitalizations Reference group
P-value for
trend <0.001
1 rehospitalizations -0.024 0.007
2 rehospitalizations -0.031 0.009
3 rehospitalizations -0.055 0.001
Age (per year) 0.002 0.001 0.014
(Age - 50)3+ -3.33*E-06
(Age - 65)3+ 6.66*E-06
(Age - 80)3+ -3.33*E-06
Male 0.054 0.009 <0.001
History of diabetes -0.041 0.009 0.007
History of 2 AMIs -0.061 0.009 <0.001
History of stroke/TIA -0.074 0.014 <0.001
History of PVD -0.046 0.012 <0.001
History of COPD -0.035 0.013 0.023
US/Canadian origin Reference group
<0.001 (F-test)European origin -0.060 0.009
Latin American origin 0.014 0.013
AMI, acute myocardial infarction;COPD,chronic obstructive pulmonary disease; PVD,periph-
eral vessel disease;TIA, transitory ischemic attack; +, only include term if difference > 0.
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Conclusions
NYHA class and number of CV rehospitalizations are estab-
lished proxies for CHF progression and can be linked to utilities
when used as health states in a decision–analytic Markov model.
If feasible, the NYHA class is preferable because its estimates are
less sensitive to interaction with population age.
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